Kaplan-meier Survival Analysis

At each observed event time, the estimate uses the subjects still under observation immediately beforehand. It multiplies the previous survival probability by the proportion of that risk set that remains event-free after the event. This product-limit calculation lets the curve incorporate changing numbers at risk rather than treating every participant as observed for the entire study.

Censoring records that a subject leaves observation or reaches follow-up without the event; it does not count as disease progression, recurrence, recovery, or death. The individual contributes information up to the last observed time, while the estimate adjusts the number remaining under observation for later intervals. This distinction helps avoid misclassifying incomplete follow-up.

Each downward step occurs at an observed event time, while flat stretches indicate intervals with no recorded event. The timing and frequency of steps show how event-free probability changes across follow-up. In neuroscience, this pattern can illustrate whether progression, recurrence, neurological recovery, or death accumulates earlier or later in a patient group.

Group-specific curves place time-to-event patterns side by side, helping researchers identify differences in disease trajectories or outcomes after injury or treatment. A separation in estimated event-free probabilities can support evaluation of prognosis and therapeutic effectiveness. The comparison remains focused on when outcomes occur, not solely on whether an outcome eventually occurred.

Researchers need follow-up time for each subject, an indication of whether the event occurred, and identification of observations that were censored. They then order the observed event times and update survival probabilities interval by interval. For neuroscience studies, the event definition must correspond to a meaningful endpoint such as progression, recurrence, recovery, or death.

It is useful when participants have different observation lengths or when some remain event-free at the end of follow-up. The method can accommodate these incomplete observations while estimating time-related outcomes after neurological injury, during disease progression, or following treatment. This makes it relevant for studying prognosis and clinically meaningful disease trajectories.

Because the estimate is updated at successive event times, the analysis preserves the timing of outcomes across follow-up. Researchers can compare groups after treatment and examine whether event-free probability changes differently over time. In neuroscience, that perspective can distinguish an early versus later pattern of recurrence, progression, recovery, or death, supporting a more informative assessment of therapeutic effect.